Dr Amanda Dalby PhD

Amanda Dalby

Institute of Immunology and Immunotherapy
Process Development and Training Manager

Contact details

First Floor ITM
Heritage Building
University of Birmingham
B15 2TT

Amanda is the Process Development and Training Manager for the recently established Centre for Advanced Therapies Manufacturing Training at the University of Birmingham. We are one of three centres established by the Advanced Therapies Skills Training Network (ATSTN). The idea of the network is to help upskill in the areas of cell and gene therapy. We are delivering courses and personal development to students, University staff, hospital staff, as well as people from industry. We are also providing outreach activities to local schools and colleges, including demos of cell and gene therapy using state of the art VR technology. Discover more about the Centre.


  • PhD in Haematology, University of Cambridge, 2017
  • MRes in Cardiovascular Science, University of Cambridge, 2013
  • BSc (Hons) in Human Genetics, Newcastle University, 2012


Amanda’s current project involves using light sheet microscopy to try and understand more about how the process of fibrinogen uptake occurs in live megakaryocytes, in real time. Knocking-out a number of genes believed to play an important role in the uptake of fibrinogen in megakaryocytes, we can also look at how this process is altered in disease. We can even begin to explore if this mechanism of uptake can be useful for delivering proteins or drugs to platelets produced in vitro.

Amanda completed her PhD in Haematology in 2017, under the supervision of Dr Cedric Ghevaert, at the University of Cambridge. This PhD focused on deriving megakaryocytes and platelets from human induced pluripotent stem cells, using a technique known as ‘Forward Programming’. With a focus on producing platelets in vitro for use in transfusion medicine, Amanda produced an inducible stem cell line capable of forward programming, using genome editing techniques. This work will help to facilitate the future transition from small-scale lab production to large-scale clinical production of platelets. This inducible stem cell line is also an important tool for researchers interested in understanding more about how megakaryocytes develop and mature to form functional platelets. Using this stem cell line and genetic engineering approaches, such as CRISPR/Cas9, offers a powerful approach to interrogate genes of interest believed to play a critical role in the development and function of megakaryocytes.

Amanda is a STEM ambassador and also tutors an A-Level student in Biology through The Access Project, aimed at helping to get underprivileged students into higher education. Amanda received several awards during her PhD, including two best student speaker prizes at conferences and best PhD poster at the L’Oréal-UNESCO for Women in Science Awards, in 2017. As part of a public engagement initiative, Amanda and colleagues were filmed answering questions posed by the public surrounding their research. For this, they were nominated for a public engagement award by the Cambridge Stem Cell Institute.


Main research interests:

  • The development and maturation of megakaryocytes and platelets, and understanding how gene mutations identified in patients with bleeding disorders affect this process.

Research Groups:

Other activities

  • Committee member for Team Science (2018-present)
  • Head of the Platelet Group Green Impacts Lab (2018-present)
  • STEM Ambassador (2018-present)


  • Watson SP, Dalby A. Anagrelide is an anti-megakaryocytic and not an anti-platelet agent. Platelets. 2018.
  • Dalby A, Ballester-Beltrán J, Lincetto C, Mueller A, Foad N, Evans A, Baye J, Turro E, Moreau T, Tijssen MR, Ghevaert C. Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision. Stem Cell Reports. 2018.
  • Futterer J, Dalby A, Lowe GC, Johnson B, Simpson MA, Motwani J, Williams M, Watson SP, Morgan NV, UK GAPP Study Group. Mutation in GNE is associated with severe congenital thrombocytopenia. Blood. 2018 June.
  • Moreau T, Evans AL, Vasquez L, Tijssen MR, Yan Y, Trotter MW, Howard D, Colzani M, Arumugam M, Wu WH, Dalby A, Lampela R, Bouet G, Hobbs CM, Pask DC, Payne H, Ponomaryov T, Brill A, Soranzo N, Ouwehand WH, Pedersen RA, Ghevaert C. Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. Nature communications. 2016.

View all publications in research portal